

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Lumigan 0.3 mg/ml eye drops, solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml contains 0.3 mg bimatoprost.

For excipients, see 6.1.

3. PHARMACEUTICAL FORM

Eye drops, solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension.

As monotherapy in patients:

- insufficiently responsive to first-line therapy
- intolerant or contra-indicated to first-line therapy

As adjunctive therapy to beta-blockers.

4.2 Posology and method of administration

The recommended dose is one drop in the affected eye(s) once daily, administered in the evening. The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect.

If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.

Use in children and adolescents (under the age of 18):

Lumigan has only been studied in adults and therefore its use is not recommended in children or adolescents.

Use in hepatic and renal impairment:

Lumigan has not been studied in patients with renal or hepatic impairment and should therefore be used with caution in such patients.

4.3 Contraindications

Hypersensitivity to bimatoprost or to any of the excipients.

4.4 Special warnings and special precautions for use

Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation since these have been observed during treatment with Lumigan. Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated. The change in iris pigmentation occurs slowly and may not be noticeable for several months.

Lumigan contains the preservative benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration.

Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since Lumigan contains benzalkonium chloride, monitoring is required with frequent or prolonged use in dry eye patients or where the cornea is compromised.

Lumigan has not been studied in patients with compromised respiratory function and should therefore be used with caution in such patients. In clinical studies, in those patients with a history of a compromised respiratory function, no significant untoward respiratory effects have been seen.

Lumigan has not been studied in patients with heart block more severe than first degree or uncontrolled congestive heart failure.

Lumigan has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma.

Cystoid macular oedema has been uncommonly reported (>0.1% to <1%) following treatment with Lumigan and should therefore be used with caution in patients with known risk factors for macular oedema (e.g. aphakic patients, pseudophakic patients with a torn posterior lens capsule).

4.5 Interaction with other medicinal products and other forms of interaction

No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) following ocular dosing. Bimatoprost is biotransformed by any of multiple enzymes and pathways, and no effects on hepatic drug metabolising enzymes were observed in preclinical studies. Therefore, specific interaction studies with other medicinal products have not been performed with Lumigan.

In clinical studies, Lumigan was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.

Concomitant use of Lumigan and antiglaucomatous agents other than topical beta-blockers has not been evaluated during adjunctive glaucoma therapy.

4.6 Pregnancy and lactation

Pregnancy

The safety of Lumigan has not been studied in pregnant women. Studies in rodents produced species-specific abortion at systemic exposure levels 33- to 97-times that achieved in humans after ocular administration. No drug related developmental effects were observed (see section 5.3). Lumigan should not be used during pregnancy unless clearly necessary.

Lactation

It is not known if bimatoprost is excreted in human milk, however, this substance is excreted in rat milk after intravenous administration. It is recommended that Lumigan is not used in nursing mothers.

4.7 Effects on ability to drive and use machines

Bimatoprost is not expected to affect the ability to drive and use machines. As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.

4.8 Undesirable effects

In clinical studies, over 1800 patients have been treated with Lumigan. On combining the data from phase III monotherapy and adjunctive Lumigan usage, the most frequently reported treatment-related adverse events were: growth of eyelashes in up to 45%, conjunctival hyperaemia (mostly trace to mild) in up to 44%, and ocular pruritus in up to 14% of patients. Less than 9 % of patients discontinued due to any adverse event.

The following undesirable effects definitely, probably or possibly related to treatment were reported during clinical trials with Lumigan. Most were ocular, mild to moderate, and none was serious:

Ocular effects

Very common (>10%): conjunctival hyperaemia, growth of eyelashes, ocular pruritus.

Common (>1% to <10%): allergic conjunctivitis, asthenopia, blepharitis, cataract, conjunctival oedema, corneal erosion, eye discharge, eyelash darkening, eyelid erythema, eyelid pruritus, eye pain, foreign body sensation, increased iris pigmentation, ocular burning, ocular dryness, ocular irritation, photophobia, pigmentation of periocular skin, superficial punctate keratitis, tearing, visual disturbance and worsening of visual acuity

Uncommon (>0.1% to <1%): blepharospasm, cystoid macular oedema, eyelid oedema, eyelid retraction, iritis, retinal haemorrhage, uveitis.

Systemic effects

Body as a whole

Common (>1% to <10%): headache

Uncommon (>0.1% to <1%): asthenia, infection (primarily colds and upper respiratory tract infections)

Gastrointestinal effects

Common (>1% to <10%): elevated liver function

Nervous system effects

Uncommon (>0.1% to <1%): dizziness

Cardiovascular

Common (>1% to <10%): hypertension

Metabolic

Uncommon (>0.1% to <1%): peripheral oedema

Skin

Uncommon (>0.1% to <1%): hirsutism

4.9 Overdose

No case of overdose has been reported, and is unlikely to occur after ocular administration.

If overdosage occurs, treatment should be symptomatic and supportive. If Lumigan is accidentally ingested, the following information may be useful: in two-week oral rat and mouse studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m² is at least 70-times higher than the accidental dose of one bottle of Lumigan in a 10 kg child.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other antiglaucoma preparations;

ATC code: S 01 EX

The mechanism of action by which bimatoprost reduces intraocular pressure in man is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow. Reduction of the intraocular pressure starts approximately 4 hours after the first administration and maximum effect is reached within approximately 8 to 12 hours. The duration of effect is maintained for at least 24 hours.

Bimatoprost is a potent ocular hypotensive agent. It is a synthetic prostamide, structurally related to prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$), that does not act through any known prostaglandin receptors. Bimatoprost selectively mimics the effects of newly discovered biosynthesised substances called prostamides. The prostamide receptor, however, has not yet been structurally identified.

During 12 months' monotherapy treatment, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm Hg. At any visit, the mean diurnal IOP values measured over the 12-month study period differed by no more than 1.3 mmHg throughout the day and were never greater than 18.0 mmHg.

Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and bimatoprost lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg.

Limited experience is available with the use in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.

No clinically relevant effects on heart rate and blood pressure have been observed in clinical trials.

5.2 Pharmacokinetic properties

Bimatoprost penetrates the human cornea and sclera well *in vitro*. After ocular administration, the systemic exposure of bimatoprost is very low with no accumulation over time. After once daily ocular administration of one drop of 0.03% bimatoprost to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing. Mean C_{max} and $AUC_{0-24hrs}$ values were similar on days 7 and 14 at approximately 0.08 ng/ml and 0.09 ng•hr/ml respectively, indicating that a steady drug concentration was reached during the first week of ocular dosing.

Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 l/kg. In human blood, bimatoprost resides mainly in the plasma. The plasma protein binding of bimatoprost is approximately 88%.

Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.

Bimatoprost is eliminated primarily by renal excretion, up to 67% of an intravenous dose administered to healthy volunteers was excreted in the urine, 25% of the dose was excreted via the faeces. The elimination half-life, determined after intravenous administration, was approximately 45 minutes; the total blood clearance was 1.5 l/hr/kg.

Characteristics in elderly patients:

After twice daily dosing, the mean AUC_{0-24hr} value of 0.0634 ng•hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng•hr/ml in young healthy adults. However, this finding is not clinically relevant as systemic exposure for both elderly and young subjects remained very low from ocular dosing. There was no accumulation of bimatoprost in the blood over time and the safety profile was similar in elderly and young patients.

5.3 Preclinical safety data

Monkeys administered ocular bimatoprost concentrations of $\geq 0.03\%$ daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure. The increased iris pigmentation appears to be caused by increased stimulation of melanin production in melanocytes and not by an increase in melanocyte number. No functional or microscopic changes related to the periocular effects have been observed, and the mechanism of action for the periocular changes is unknown.

Bimatoprost was not mutagenic or cytogenic in a series of *in vitro* and *in vivo* studies.

Bimatoprost did not impair fertility in rats up to doses of 0.6 mg/kg/day (approximately 103-times the intended human exposure). In embryo/foetal developmental studies abortion, but no developmental effects were seen in mice and rats at doses that were at least 860-times or 1700-times higher than the dose in humans, respectively. These doses resulted in systemic exposures of at least 33- or 97-times higher, respectively, than the intended human exposure. In rat peri/postnatal studies, maternal toxicity caused reduced gestation time, foetal death, and decreased pup body weights at ≥ 0.3 mg/kg/day (at least 41-times the intended human exposure). Neurobehavioural functions of offspring were not affected.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride
Sodium chloride
Sodium phosphate dibasic heptahydrate
Citric acid monohydrate
Hydrochloric acid or sodium hydroxide (to adjust pH)
Purified water

6.2 Incompatibilities

None known.

6.3 Shelf life

2 years.

4 weeks after first opening.

6.4 Special precautions for storage

No special precautions for storage.

Chemical and physical in-use stability has been demonstrated for 28 days at 25°C. From a microbiological point of view, the in-use storage times and conditions are the responsibility of the user and would normally not be longer than 28 days at 25°C.

6.5 Nature and contents of container

White opaque low density polyethylene bottles with polystyrene screw cap. Each bottle has a fill volume of 3 ml.

6.6 Instructions for use and handling

None.

7. MARKETING AUTHORISATION HOLDER

Allergan Pharmaceuticals (Ireland) Ltd
Castlebar Road
Westport
Co. Mayo
Ireland

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10. DATE OF REVISION OF THE TEXT

ANNEX II

- A. MANUFACTURING AUTHORISATION HOLDER
RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OF THE MARKETING AUTHORISATION**

A MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Allergan Pharmaceuticals Ireland Ltd.
Castlebar Road, Westport,
County Mayo
IRELAND

B CONDITIONS OF THE MARKETING AUTHORISATION

• **CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER**

Medicinal product subject to medical prescription

• **OTHER CONDITIONS**

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

LUMIGAN 0.3 mg/ml, eye drops, solution

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Bimatoprost 0.3 mg/ml

3. LIST OF EXCIPIENTS

Benzalkonium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate, sodium chloride, hydrochloric acid or sodium hydroxide (to adjust pH) and purified water

4. PHARMACEUTICAL FORM AND CONTENTS

Eye drops, solution 3 ml

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Ocular use. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Remove contact lenses before use.

8. EXPIRY DATE

EXP {MM/YYYY}

Discard four weeks after first opening.

Opened:

9. SPECIAL STORAGE CONDITIONS

There are no special storage instructions

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Allergan Pharmaceuticals (Ireland) Ltd
Castlebar Road
Westport
Co. Mayo
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000

13. MANUFACTURER'S BATCH NUMBER

Batch: {number}

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
BOTTLE

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

LUMIGAN 0.3 mg/ml, eye drops, solution
Bimatoprost
Ocular use

2. METHOD OF ADMINISTRATION

Read the package leaflet before use.

3. EXPIRY DATE

Discard 4 weeks after first opening
Exp: {MM/YYYY}

4. BATCH NUMBER

Batch: {number}

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

3 ml

B. PACKAGE LEAFLET

PACKAGE LEAFLET

Read all of this leaflet carefully before you start taking this medicine.

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.

In this leaflet:

1. What Lumigan is and what it is used for
2. Before you use Lumigan
3. How to use Lumigan
4. Possible side effects
5. Storing Lumigan
6. Further information

Lumigan 0.3 mg/ml eye drops, solution
Bimatoprost

- The active substance is bimatoprost 0.3 mg/ml.
- The other ingredients are benzalkonium chloride (preservative), sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water. Small amounts of hydrochloric acid or sodium hydroxide may be added to keep the level of acid (pH levels) normal.

The marketing authorisation holder and manufacturer for Lumigan is:
Allergan Pharmaceuticals (Ireland) Ltd
Castlebar Road
Westport
Co. Mayo
Ireland.

1. WHAT LUMIGAN IS AND WHAT IT IS USED FOR

Lumigan is a colourless, clear eye drop solution in a plastic bottle with a screw cap. Each bottle is just under half full and contains three millilitres of solution. This is enough for 4 weeks' usage.

Lumigan is an antiglaucoma preparation. It belongs to a group of medicines called prostamides.

Lumigan eye drops are used to reduce high pressure in the eye. This high pressure can lead to a disease called glaucoma. If the high pressure is not reduced, it could eventually damage your sight.

Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid is constantly being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up. Lumigan works by increasing the amount of liquid that is drained. This reduces the pressure inside the eye.

Lumigan may be used on its own or with other drops called beta-blockers which also reduce pressure.

2. BEFORE YOU USE LUMIGAN

Do not use Lumigan if you are allergic to bimatoprost or any of the other ingredients.

Take special care with Lumigan if any of the following apply.

- You wear contact lenses. Don't use the drops when you are wearing your lenses. Wait 15 minutes after using the drops before you put your lenses back in. A preservative in Lumigan called benzalkonium chloride may cause eye irritation and can discolour soft contact lenses.
- Talk to your doctor, if:
 - You have any breathing problems.
 - You have liver or kidney problems.

Lumigan may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too. The colour of your iris may also go darker over time. These changes may be permanent. The change may be more noticeable if you are only treating one eye.

People under 18 must not use Lumigan.

Pregnancy

Ask your doctor or pharmacist for advice before taking any medicine.

Breast-feeding

Lumigan may get into breast milk so you should not breast-feed while you are taking Lumigan.

Driving and using machines

Your sight may become blurred for a short time just after using Lumigan. You should not drive or use machines until your sight is clear again.

Using other medicines


Please tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines, even those not prescribed.

3. HOW TO USE LUMIGAN

Lumigan should only be applied to the eye. Normally, you should put one drop of Lumigan in each eye that needs treatment, once every day, in the evening, following the instructions for use below. Always use Lumigan exactly as your doctor has instructed you. If you use Lumigan with another eye drop, leave at least five minutes between putting in Lumigan and then the other drops.

Instructions for use:

You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first use it.



1. Wash your hands. Tilt your head back and look at the ceiling.
2. Gently pull down the lower eyelid until there is a small pocket.
3. Turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment.
4. Let go of the lower lid, and close your eye for 30 seconds.

If a drop misses your eye, try again.

To help prevent infections, do not let the tip of the bottle touch your eye or anything else. Put the cap back on and close the bottle straight after you have used it.

If you use more Lumigan than you should, it is unlikely to cause you any serious harm. Put your next dose in at the usual time. If you are worried, talk to your doctor or pharmacist.

If you forget to take Lumigan, use a single drop as soon as you remember, and then go back to your regular routine. Do not take two doses to make up for the one that you missed.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Lumigan can have side effects. Most of the side effects are not serious.

Very common side effects

These may affect more than one person in every 10 people

Affecting the eye

- Longer eyelashes (up to 45% of people)
- Slight redness (up to 44 % of people)
- Itchiness (up to 14% of people)

Common side effects

These may affect up to nine people in every 100 people

Affecting the eye

- An allergic reaction in the eye
- Tired eyes
- Sensitivity to light
- Darker skin colour around the eye
- Darker eyelashes
- Pain
- A feeling that something is in your eye
- Sticky eyes
- Darker iris colour
- Difficulty in seeing clearly
- Irritation
- Burning
- Inflamed, red and itchy eyelids
- Tears
- Dryness
- Swelling of the see-through layer which covers the surface of the eye
- Cataract
- Small breaks in the surface of the eye, with or without inflammation

Affecting the body

- Headaches
- An increase in blood-test results that show how your liver is working
- Increased blood pressure

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

5. STORING LUMIGAN

You must throw away the bottle four weeks after you first opened it, even if there are still some drops left. This will prevent infections. To help you remember, write down the date you opened it in the space on the box.

Keep out of the reach and sight of children.

Keep the container tightly closed to prevent contamination. Do not use Lumigan after the expiry date (marked "EXP:") on the bottle label and box.

6. FURTHER INFORMATION

For any information about this medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Allergan NV/SA
Antwerp Business Centre
B-2000 Antwerpen
Tél/Tel: 03 302 4670

Danmark

Allergan A/S
Produktionsvej 14
DK-2600 Glostrup
Tlf: 4494 0810

Deutschland

Pharm-Allergan GmbH
Rudolf-Plank-Strasse 31
D-76275 Ettlingen
Tel: 07243 501 789

Ελλάδα

Alvia A.E.
18ο χλμ Λεωφ. Μαραθώνος
GR-153 51 Παλλήνη Αττικής
Τηλ: 01 603 9795

España

Allergan S.A.
Avenida de la Industria 24
Tres Cantos
E-28760 Madrid
Tel: 91 807 6161

France

Allergan France S.A.
Sophia Antipolis, Font de L'orme
1198 Av. Docteur Maurice Donat
F-06250 Mougins
Tél: 04 9292 4400

Ireland

Allergan Ltd
Coronation Road
High Wycombe
Bucks, HP 12 3SH
United Kingdom
Tel: 00 44 1494 427026

Italia

Allergan S.p.A
Via S.Quasimodo 134/138
I-00144 Roma
Tel: 06 509 561

Luxembourg/Luxemburg

Allergan NV/SA
Antwerp Business Centre
B-2000 Antwerpen
Belgique/Belgien
Tél: 00 32 3 302 4670

Nederland

Allergan B.V.
Wattbaan 48 II
NL-3439 ML Nieuwegein
Tel: 030 607 4666

Norge

Allergan Norden A.B
Johanneslundsvagen 2
S-194 81 Upplands Väsby
Sverige
Tlf: 00 46 8 594 100 00

Österreich

Pharm-Allergan GmbH
Landstrasser Hauptstrasse 60
A-1030 Wien
Tel: 01 713 7751

Portugal

Allergan SA.
R General Ferreira Martins, 10-7 D
Miraflores
P-1495 Lisboa
Tel: 21 410 7096

Suomi/Finland

Allergan Norden A.B
Rajatorpantie 41C
FIN-01640 Vantaa
Puh/Tel: 09 8520 2192

Ísland

Pharmaco hf.
Hörgatúni 2
IS-210 Garðabær
Sími: 535 7000

Sverige

Allergan Norden A.B
Johanneslundsvagen 2
S-194 81 Upplands Väsby
Tel: 08 594 100 00

United Kingdom

Allergan Ltd
Coronation Road
High Wycombe
Bucks, HP12 3SH
Tel: 01494 427026

This leaflet was last approved on